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Abstract: In the past, immunization programs worldwide mainly focused on the delivery of infant and early childhood 
vaccines. An increasing awareness of the importance of investing in adolescents’ health has led to the introduction of new 
vaccines targeted specifically to adolescents over the last ten years: this has improved the adolescent’s opportunities to 
protect from certain diseases for which they are at an increased risk. Safe and effective vaccines against human papilloma 
virus, Neisseria meningitides and Bordetella pertussis are recommended in many parts of the world; nevertheless,  
vaccination coverage in this age group is relatively low compared to coverage in infants. Barriers to adolescent immuniza-
tion are believed to be complex and multifactorial but overcoming these barriers will be of primary importance for 
the future. 
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INTRODUCTION 
 Until the 1990s, infants and children received priority in 
immunization: in fact the majority of the vaccines were ad-
ministered during infancy and a series of public health initia-
tives were directed to immunize infants and young children; 
on the other hand no vaccines were specifically available and 
recommended for adolescents [1]. Thus in 1997 the Ameri-
can Academy of Pediatrics defined the adolescents as “the 
orphans of immunization practices” [2].  
 Over the last ten years, adolescents have received  
increasing attention and the importance of continued 
immunizations in this age group is now recognized. A his-
torically unprecedented number of new vaccines and rec-
ommendations for adolescents have been made by CDC’s 
Advisory Committee on Immunization Practices (ACIP) in 
the last few years. The recommendations are based on the 
evidence that teenagers have an increased risk of infection of 
some vaccine preventable diseases (pertussis, meningococcal 
disease and papilloma virus related diseases) and they repre-
sent a reservoir for infection to spread to other age groups, 
such as infants and the elderly. Moreover, due to the success 
of the routine childhood immunization, the age of distribu-
tion of some diseases has shifted from infants and young 
children to older age groups exposing adolescents to an in-
creased risk of disease [3]. 
 The adolescent vaccination schedule comprises 3 types of 
immunization opportunities: booster vaccinations [e.g. the 
combined tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis (Tdap)], catch-up on missed vaccinations 
but also new primary immunization with recently approved 
vaccine specifically targeted to adolescents such as menin-
gococcal conjugate vaccine and the bivalent and quadrivalent  
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human papillomavirus (HPV) vaccine, currently available in 
many countries. During adolescence booster doses are re-
quired for many vaccines routinely given during infancy and 
early childhood because immunity wanes over time and they 
increase the duration of protection through late adolescence 
and adulthood while “catch-up” vaccinations provides an 
additional opportunity for initiation or completion of infant 
and early childhood immunization.  
 From a public health point of view immunization of ado-
lescents is essential not only for protecting the individual but 
also for protecting the community as a whole because 
achieving and maintaining high immunization rates in the 
general population is critical for disease prevention. Fur-
thermore high vaccination coverage rate in adolescents is a 
prerequisite for long-term protection in adult life.  
 Despite these considerations and the evident example 
given by the success of infant and childhood vaccination 
programs in terms of prevention of many infectious diseases 
such as polio, measles, rubella, and smallpox, adolescent 
immunization rates have remained low. Few large studies on 
vaccination coverage in adolescents have been conducted, 
because, in comparison with younger age groups, it is  
harder to reach them and to obtain reliable data. In the USA 
vaccination coverage among adolescents increased 
substantially from 1997 to 2003 [4] and, in particular, from 
2006 [5] to 2009 [6] but the Healthy People 2010 goals 
(vaccination coverage > 90%) [7] for preteens and teens 
aged 13-15 are not being met for many of the vaccines for 
which goals were set. Measured against the Healthy People 
2010 targets of 90% coverage, vaccination coverage for 
adolescents aged 13-15 years was 89.0% for 2 doses of 
measles-mumps-rubella, 91.2% for 3 doses of Hepatits B, 
74.7% for 1 dose of diftheria-tetanus-pertussis and 90.5% 
for 1 dose of varicella.  
 Few and partial data about the adolescent vaccination 
coverage in European countries are available: nevertheless 
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studies shown that, as in the United States, immunization 
rates in this age group are not satisfactory [8, 9]. 
ADOLESCENT IMMUNIZATION: A BIG CHALLENGE 
 The barriers to adolescent immunization are believed to 
be complex and multifactorial. Different factors contribute to 
low adolescent immunization rates despite the establishment 
of age-specific recommendations in many countries: adoles-
cents, parents and health care providers play an essential role 
in the acceptance of immunization.  
The Role of Adolescents 
 Adolescence is a crucial time during which individuals 
establish behavioral patterns that have profound effects on 
adult health. Many adolescents consider themselves to be 
adults, capable of choosing their own paths and making their 
own choices and they are actively involved in healthcare 
decisions. Therefore one of the big barriers to immunization 
is the adolescent vaccine acceptance. Needle-phobia, multi-
ple dose vaccines, misperceptions regarding the safety of 
vaccines, a lack of knowledge about the importance of  
immunizations and their health benefits, unawareness of  
being at risk for infectious diseases and peer-pressure are 
determinant factors for the vaccine acceptance and vary by 
age [10-12]. In addition the role of Internet, in particular 
blogs, regarding the diffusion of misperceptions about the 
safety of vaccines has been recently underlined [13]. In fact 
Internet is a primary source of information for adolescents 
and the presence of internet sites presenting inaccurate  
information about vaccine safety could be a further impor-
tant barrier for the implementation of immunizations in this 
age group [14]. 
 Another factor that should be considered is the relation-
ship between the adolescent and the use of preventive care 
services. Even though during the past 20 years the number of 
clinical preventive care services recommended for adoles-
cents by national organizations has increased considerably, it 
is well known that the use of preventive health care service 
is low and declines from childhood to adolescence. Only 9% 
of all adolescents’ health care visits are for preventive care 
with the lowest rate recorded in older adolescents aged 15-19 
years compared to younger adolescents aged 11-14 years 
[15]. The utilization level of preventive care visits correlates 
with the socioeconomic status and the possibility of reim-
bursement [16, 17]. In a more recent study one-third of ado-
lescents had no preventive care visits from 13 to 17 years 
old, and another 40% only had a single visit [18]. This lack 
of access to healthcare services has led to missed opportuni-
ties for vaccination for this age group and to low vaccination 
coverage rate. In this context the feasibility of delivering 
vaccines to adolescents in settings outside of physician’s 
office such as school and home should also be considered 
[19]. 
The Role of Parents 
 Adolescence is a time period when adolescent-parent 
dynamics change: teenagers usually develop a new sense of 
autonomy from their mother and father and begin to make 
decisions that impact them for the rest of their lives [20]. 
Nevertheless parental involvement is clearly an important 
influence in decision-making: parental attitudes and beliefs 
are a major factor in adolescent vaccine compliance [21]. 
Moreover parents provide concrete support such as transpor-
tation, insurance coverage and authorization for vaccinations 
to take place [22]. 
 Parental attitudes towards vaccination are not homogene-
ous and are influenced by different factors [23-25]. Parents’ 
perceptions of potential morbidity and mortality for vaccine 
preventable diseases, perceptions of vaccine efficacy and 
safety and the overall attitude towards vaccination, influ-
enced by past experience with children’s immunizations, 
were associated with vaccine acceptance [26, 27]. On the other 
hand, lower propensity for vaccination seems to be related  
to underestimation of infection and lack of knowledge  
regarding new vaccines, in particular HPV vaccine [28, 29]. 
 A recent study showed that, although parents believe that 
vaccines are a good way to protect their children and adoles-
cents from disease, these same parents express concern re-
garding the potential adverse effects and especially seem to 
question the safety of novel vaccines. This concern can lead 
to a high rate of vaccine refusal: in fact overall 11.5% of the 
parents of children aged  17 had refused at least 1 recom-
mended vaccine in particular HPV (56%), followed by 
varicella, meningococcal conjugate and measles-mumps-
rubella vaccine [30]. 
 An additional factor that needs to be considered is the 
influence of ethnic and socioeconomic milieu in parental 
vaccine acceptance. Several previous studies, looking at the 
question of acceptability of the vaccines among parents in 
various populations, in particularly HPV vaccine, showed 
different results. Some authors reported that Hispanic and 
black individuals have a higher rate of negative attitudes 
towards immunization than white individuals [31-33], while 
other studies showed that the Caucasians are less likely to 
support the uptake of the vaccines than parents of other races 
and minor ethnicities [34-36]. No correlation between race 
and parental vaccine acceptance was found in other studies 
[37-39]. Nevertheless it is reasonable to suppose that differ-
ent socio-cultural attitudes towards vaccination and a differ-
ent perception of risk of catching a disease are often seen in 
different populations and might influence vaccination 
choices; however the reasons why differences exist between 
racial ethnic groups remain largely unknown [40]. 
 The effect of socioeconomic status and education in vac-
cine acceptance is still under debate: findings suggest mixed 
effects of socioeconomic status, with lower education asso-
ciated with higher acceptability, while higher income is as-
sociated with higher acceptability [41]. 
 Finally, the dramatic decline observed in vaccine pre-
ventable diseases compared to the pre-vaccine era has led to 
parents’ lack of experience with the morbidity and mortality 
associated with these diseases [42]. This fact has led to a 
decrease in the perceived importance of vaccination as a 
valuable preventive health intervention and could hinder the 
diffusion of vaccines in the future. 
The Role of Health Care Providers 
 Physicians have a role of primary importance in promot-
ing a healthy lifestyle for adolescents and both pediatricians 
and family physicians play a critical role in vaccine counsel-
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ing. A good communication between the healthcare provider, 
parents and patients is essential for vaccine compliance and 
the physician’s ability to establish a confidential relationship 
with the adolescent could be an important factor for promot-
ing immunization.  
 Healthcare providers are one of the main information 
sources about vaccines for parents and since their recom-
mendations are considered to be a strong predictor of vaccine 
acceptance, providing clear information about vaccine effi-
cacy and security both to parents and adolescents is essential 
[43, 44]. In order to do so, physicians should have an appro-
priate knowledge of vaccines: in particular a good knowl-
edge of those specifically targeted to adolescents is of pri-
mary importance and may be the most decisive factor rec-
ommending particular vaccines [45]. 
 Healthcare provider attitudes towards adolescents’ vacci-
nation are quite different: even though most physicians rec-
ommend appropriate vaccinations to their adolescent patients 
and include immunization activities in preventive health vis-
its, they experience barriers to adolescent immunization, 
particularly as adolescents grow up [11]. A recent study of 
healthcare barriers in delivering HPV vaccine showed that 
personal beliefs towards vaccination in general (and specifi-
cally to HPV vaccine) and the importance of adhering to the 
official recommendations are associated with higher rate of 
vaccination. Nevertheless high financial costs and encounter-
ing patients (more often patients' parents) who have negative 
perceptions of vaccine are the strongest barriers to immuni-
zation reported by providers [46]. Thus, overcoming these 
barriers in addition to a continuous physician education on 
vaccines and the creation of an alliance among adolescent 
and health care professionals is crucial for increasing adoles-
cents’ immunization rates. 
NEW VACCINES FOR ADOLESCENTS: WHEN, 
WHY AND WHAT? 
 The term adolescence is commonly used to define the 
period of life between childhood and adulthood. Even 
though adolescence is a recognizable phase of life, its onset 
and its end are not always easy to define. The exact age 
range of adolescents has been largely debated over the years 
because adolescence varies considerably across cultures and 
within individuals. This poses problems for practitioners 
when adolescent patients require care in facilities with re-
strictive age limits. Despite the large variation in adolescence 
definition in term of cut-off age range, actually the American 
Academy of Pediatrics and the American Medical Associa-
tion have defined adolescence as a time period between the 
age of 11 and 21 [47].  
  In 1996 specific recommendations for the immunization 
of adolescents were developed in the USA to improve  
vaccination coverage among adolescents [48]. Over the years 
an extensive review of all aspects of vaccines (e.g., effec-
tiveness, safety, cost) and an update of adolescent recom-
mendations were made by ACIP. A milestone in adolescent 
immunization was the licensing in 2005 of three vaccines 
[quadrivalent meningoccal conjugate (MCV4), HPV and the 
Tdap] specifically targeted for this age group: in fact their 
introduction has opened new preventive possibilities for 
adolescents. 
 The CDC in collaboration with the American Academy 
of Pediatrics update periodically the adolescent immuniza-
tion schedule considering additional data on efficacy, safety 
and cost-effectiveness of vaccines but also trends in disease 
epidemiology. We summarize below the three main vaccines 
for adolescents against diphtheria-tetanus-pertussis, HPV 
and Neisseria meningitidis.  
DIFTHERIA-TETANUS-PERTUSSIS VACCINE 
 Over the past several decades, the introduction of the 
routine childhood vaccination programs against diphtheria, 
tetanus and pertussis has reduced the morbidity and mortality 
associated with these diseases [49, 50]. Although cases of 
diphtheria and tetanus are very rare in countries with suc-
cessful vaccination programs, in the past two decades resur-
gence of pertussis has been reported in many areas of the 
world [51]. This increase in incidence of pertussis reflects 
different factors (waning in vaccine-induced immunity to 
pertussis in the 4–12 years after vaccination and a decrease 
of natural boosting of immunity) and has been associated 
with a shift in age groups afflicted with pertussis [52, 53]. In 
fact before the introduction of the vaccine, pertussis mostly 
affected school-age children, but it has now shifted to very 
young infants not completely vaccinated and to adolescents 
and adults [54, 55]. In Europe the incidence of reported per-
tussis cases was higher among infants, (22 cases per 
100,000) and among those aged 10-14 (20 cases per 100,000 
inhabitants): these data indicate that adolescents are at an 
increasing risk of disease [56]. 
 Usually pertussis in adolescents has not very severe 
course and results in only mild symptoms; however the mor-
bidity may be significant since paroxysmal cough, difficulty 
in breathing, post-tussive vomiting, whoop, and difficulty in 
sleeping are reported in this age group. Complications such 
as pneumonia, rib fracture, seizure and loss of consciousness 
can occur and lead to hospitalization [57]. In addition a long 
delay in diagnosis, typically seen in adolescents, results in an 
unsuspected and uninterrupted prolonged period of infec-
tiousness and contributes to Bordetella pertussis transmis-
sion to unvaccinated young infants [58]. In this scenario the 
introduction of a booster dose of pertussis vaccine (in asso-
ciation to a boosted dose of tetanus toxoid and diphtheria 
antigens) during adolescence could prevent this cycle of 
transmission from older individuals to susceptible infants, 
reduce the incidence and prevent the morbidity of this dis-
ease. Moreover this vaccine is useful to maintain the stan-
dard of care for tetanus and diphtheria prevention: in fact 
waning immunity to tetanus and diphtheria was observed 
after primary tetanus vaccination [59].  
 The first acellular pertussis vaccines for adults and ado-
lescents were licensed in 2005: this vaccine, containing a 
reduced-dose of acellular pertussis antigen combined with 
diphtheria and tetanus toxoids (Tdap), was introduced as a 
booster on the basis of non inferiority of the serologic re-
sponse and the minor reactogenicity to the various compo-
nents compared with the pediatric formulation [60]. 
 Two different booster vaccines are currently licensed for 
adolescents: the three pertussis component Tdap booster 
vaccines and the five pertussis component ones that contain 
fimbriae types 2 and 3 in addition to detoxified pertussis  
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toxin, filamentous hemagglutinin and pertactin. These vac-
cines showed an excellent immunological response after one 
booster dose and were noninferior to the tetanus-reduce dose 
diphtheria vaccine. In adolescents they elicited robust im-
mune responses to pertussis antigens and protective levels of 
anti-diphtheria and anti-tetanus antibody after immunization. 
In terms of reactogenicity Tdap is generally well tolerated: 
local injection-site and systemic adverse events were of mild 
intensity and were resolved without sequelae [61-64]. Some 
neurologic outcomes (Bell Palsy and encephalopathy) after 
Tdap have been reported to the Vaccine Adverse Events Re-
porting System; nevertheless a recent study found no evi-
dence of an association between Tdap and encephalopathy, 
encephalitis, meningitis, paralytic syndromes, seizures, cra-
nial nerve disorders and Guillain-Barré syndrome [65]. 
Moreover no evidence for an increased risk for hematologic, 
allergic events or new onset of chronic illnesses among 
adolescents vaccinated with Tdap was seen [66]. 
Effectiveness during outbreaks was also reported [67]. 
 Vaccine-induced immunity to pertussis, like naturally 
acquired immunity against the disease, fails to induce life-
long protection. A study conducted in adolescents with the 
acellular pertussis vaccine showed an increase in antibodies 
against pertussis antigens for up to 5 years [68], nevertheless 
pertussis antibody levels were predicted to be sustained for 
at least 10 years [69]. These data support the use of a booster 
dose once every 10 years [70]. 
 The ability to coadminister Tdpa with more than one rec-
ommended vaccine at the same time without compromising 
the safety, tolerability, and immunogenicity of each vaccine 
has the potential to increase compliance in adolescents, en-
hance implementation of immunization strategies and in-
crease disease prevention [71-73]. These data support the 
ACIP recommendations for adolescent immunization for the 
use of Tdap vaccine: a single booster dose should be admin-
istered to persons aged 11-18 who have completed the rec-
ommended childhood diphtheria and tetanus toxoids and 
pertussis/diphtheria and tetanus toxoids and acellular pertus-
sis vaccination series. Moreover Tdap can be administered 
regardless of the interval since the last tetanus and diphtheria 
toxoid-containing vaccine [74]. These strategies are made to 
facilitate the use of Tdap to reduce the burden of disease and 
the risk for transmission to infants. 
HUMAN PAPILLOMA VIRUS VACCINES 
 The advent of the HPV vaccine is one of the “historic 
milestones” in the field of adolescent immunization. Twenty 
years after the introduction of human hepatitis B vaccine, the 
second opportunity to be protected from cancer through im-
munization was given by the HPV vaccine. In fact HPV in-
fection is known to cause a wide range of cancer and genital 
warts in both sexes: cancer of cervix, vulva, vagina, anus, 
penis, head, neck and bladder are known to be associated 
with different types of HPV [75]. Recently the role of HPV 
in breast and bladder has been investigated but a definitive 
relationship between these cancers and HPV infection has 
not been established [76, 77]. Adolescence is a crucial time-
period in the natural history of HPV infection: in fact HPV 
infection is usually acquired during adolescence (up to  
25 years old) and many of the risk factors for developing 
cervical cancer are typically found in adolescents. Cigarette 
smoking, a younger age at first intercourse, high number of 
sexual partners and other sexual transmitted infections are 
associated with an increase risk of invasive cervical cancer 
[78]. The incidence of infections among female adolescents 
aged 14-19 ranges from 18.2% to 24.5% [79,80] while it is 
>20% in young men [81]. A meta-analysis (considering stud-
ies published between 1995 and 2009) showed that age-
specific HPV distribution occurred with a first peak at a 
younger age (<25 years) [82]. Although, HPV infection is 
usually asymptomatic and clears without intervention [83, 
84], persistent infection (mostly due to HPV 16 and 18) is 
considered to be required for developing of high grade intra-
epithelial neoplasia of cervical, vaginal and vulvar tracts. In 
this scenario young adolescent girls are identified as the  
primary target group for most HPV immunization programs: 
in fact targeting adolescents before the onset of sexual activ-
ity and the exposure to HPV is likely to provide the greatest 
long term health benefits. 
 Two prophylactic vaccines are currently licensed in many 
countries. The quadrivalent vaccine contains HPV types 
6,11,16,18 and was the first to be approved for use among 
females aged 9-26 for prevention of vaccine HPV-type-
related cervical cancer, cervical cancer precursors, vaginal 
and vulvar cancer precursors and anogenital warts [85]. In 
fact HPV 16 and 18, classified as high risk types according 
to their oncogenic potential, are strongly associated with 
cervical cancer, while HPV 6 and 11 types are the most 
common causes of genital warts. The bivalent vaccine which 
contains HPV types 16 and 18 is indicated for the prevention 
of HPV-type-related premalignant cervical lesion and cervi-
cal cancer [86]. Both vaccines, given in a 3 shot series, have 
been shown to be highly immunogenic when administered to 
adolescent girls and young women and their efficacy against 
cervical, vulvar, vaginal premalignant lesions and genital 
wards was proved in many clinical trials [87, 88]. More research 
is being done to find out how long protection will last, and if 
a booster dose will eventually be needed: at this time there is 
not sufficient information and no booster doses are currently 
recommended [89]. 
 HPV vaccines were safety-tested before licensing and are 
continually monitored for their safety. Currently the propor-
tion of serious adverse events is below 0.1% for both  
vaccines and the most common reported side effects were 
local site reactions [90]. An increased risk of syncope was 
reported after the administration of quadrivalent vaccine: 
thus, CDC and Food and Drug Administration recommend 
observing the patient for a minimum of 15 minutes after  
vaccine administration [91]. 
 Recently the quadrivalent vaccine has been approved for 
use in boys and men aged 9-26: it is the first preventive ther-
apy against genital warts for males [92]. In fact male infec-
tion is an important concern both for the disease burden (the 
rate of genital HPV infection among males is similar to that 
in females) and for the risk of transmission to women [93]. 
This vaccine is immunogenic and prevents infection with 
HPV-6, 11, 16, and 18 and the development of related exter-
nal genital lesions in this age group: the efficacy against any 
HPV 6/11/16/18-related external genital lesion was 90.4% 
[94]. As observed previously with females, the most com-
mon adverse events were injection-site reactions, fever and 
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headache most of which were mild to moderate in intensity 
[95]. 
 In recent years the interest in using HPV vaccine in some 
special populations is increasing especially with respect to 
HIV infection. In fact the prevalence of HPV and premalig-
nant cervical lesion is several-fold higher in HIV-infected 
women than in uninfected women and HPV infections tend 
to persist longer [96]. In particular HIV-infected adolescent 
girls are particularly vulnerable with a risk three-fold higher 
for developing high-grade squamous intraepithelial lesions 
[97]. In this scenario the immunization of HIV-infected girls 
with HPV vaccines will be a major opportunity to reduce the 
burden of HPV infection in this population. Although no 
data are available for HIV-infected adolescents, in HIV-
infected children aged 7-12 the quadrivalent vaccine appears 
to be safe and immunogenic and no evidence for perturba-
tion of CD4 level or HIV viral load and unexpected adverse 
events have been reported [98]. More studies are urgently 
needed to assess the vaccine efficacy in this population. 
VACCINES AGAINST NEISSERIA MENINGITIDIS 
 Meningococcal meningitis and septicemia are a persistent 
public health concern owing to the associated morbidity and 
mortality. Even if people of all ages may be affected, a peak 
in disease incidence was reported during adolescence [99, 
100]. Moreover a higher nasopharyngeal carriage rate of 
N.meningitidis was observed in teenagers (23.7%) compared 
to other age groups [101]. The reason for this high disease 
susceptibility should be found in the typical adolescent life-
style. Studies suggested that certain behaviors influence the 
risk of nasopharyngeal carriage of N. meningitidis and inva-
sive meningococcal disease: living in crowded situations 
(pub and club visits, dormitories), marijuana use, active and 
passive smoking, sharing of drinking glasses and high num-
ber of kissing partners are associated with an increased risk 
of carriage and disease [102-105]. The burden of meningo-
coccal disease and its consequences in this age-group is 
high: infection in 15-24 year olds was more likely to be fatal 
than infection in those younger than 15 years old and poor 
long-term physical, psychological, educational and social 
outcomes were reported in adolescents survived to an inva-
sive meningococcal disease [106]. In fact major physical 
sequelae, fatigue, deficits in short and long-term memory 
and attention, slowed psychomotor speed, depressive symp-
toms, less social support, reduction in quality of life and low 
educational attainment were reported in survivors [107, 108]. 
Although early diagnosis and treatment are important in re-
ducing the morbidity and mortality associated with menin-
gococcal disease, vaccines are required for ultimate disease 
control. In fact vaccination may be a key factor for avoiding 
infection in susceptible adolescents and thus to prevent the 
mortality and morbidity in this age group. 
 Five clinically relevant meningococcal serogroups, A, B, 
C,Y and W-135, are responsible for nearly all infections 
worldwide with different geographical distribution across 
countries; overall, serogroups B, C and Y cause a substantial 
proportion of disease across all ages [109]. These data com-
bined with an increased frequency of travelling worldwide, 
underscore the need for a strong prevention strategy that 
incorporates all major serogroups [100, 110]. Currently there 
are no vaccines licensed and routinely used for serogroup B 
but quadrivalent vaccines, containing serogroup A,C,Y,W-
135, are currently licensed worldwide.  
 Polysaccharide quadrivalent vaccines have been available 
for several decades but have been little used due to poor im-
munogenicity in young children and minimal effects on na-
sopharyngeal carriage. On the basis of the limits of polysac-
charide vaccines and epidemiological changes in the circula-
tion of pathogenic serogroups in the United States, a quadri-
valent conjugate vaccine (MCV4) was developed and  
approved in 2005. Recently, another tetravalent conjugate 
meningococcal vaccine has been licensed and made available 
in the USA and in the EU [111]. Both vaccines are immuno-
genic and have shown a high tolerability profile in adoles-
cents [112]. An investigational quadrivalent (A,C,W-135,Y) 
tetanus toxoid conjugate vaccine, developed to expand  
available options for vaccination against invasive meningo-
coccal diseases, showed consistently a high rise in bacteri-
cidal titres across all serogroups when administered as a  
single dose to adolescents and the reactogenicity profile was 
clinically acceptable; nevertheless more studies are needed 
[113-115]. 
 New recommendations for the use of meningococcal con-
jugate vaccines were updated by ACIP based on new data on 
immunogenicity in high-risk groups, bactericidal antibody 
persistence after immunization, current epidemiology, vac-
cine effectiveness and cost-effectiveness of different strate-
gies for vaccination of adolescents. According to the CDC, 
adolescents aged 11 or 12 should be routinely vaccinated and 
a booster dose should be administered 5 years after the first 
dose due to waning immunity. In fact after a booster, anti-
body titres are higher than after the first dose and are ex-
pected to protect adolescents through the period of increased 
risk up to 21 years old. In addition HIV-infected adolescents 
and persons aged 2 through 54 years with persistent com-
plement component deficiency, functional or anatomic as-
plenia, should receive a 2-dose primary series administered 2 
months apart because immune response to a single dose of 
meningococcal conjugate vaccine is not sufficient in persons 
with certain medical conditions [116]. 
 Actually little is known about the real vaccine efficacy 
against meningococcal disease although recent epidemiol-
ogical data collected after the introduction of MCV4 showed 
an important reduction in incidence of meningococcal dis-
ease with an estimated effectiveness of this vaccine ranging 
from 80 to 85% up to 3 years after vaccination [117]. Never-
theless the peak in disease among teenagers has persisted, 
even after routine vaccination. Moreover the recent emer-
gence of strains with reduced antibiotics susceptibility in 
many areas of the world underlines the importance of pre-
venting meningococcal disease by vaccination [118-123] 
Thus, new strategies and more efforts to increase awareness 
of diseas susceptibility and of the importance of vaccination 
are urgently needed particularly in adolescent population.  
ADOLESCENT IMMUNIZATION IN DEVELOPING 
COUNTRIES 
 Although a considerable number of countries, including 
some low- and middle-income countries, have national rec-
ommendations to immunize adolescents, most literature 
about the administration of vaccines to adolescents comes 
from developed countries. Few data are available about ado-
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lescent immunization in developing countries. Without a 
doubt, one of the greatest barriers to the introduction of vac-
cination in developing countries is cost although the lack of 
health care infrastructure is also determinant. Delivery costs 
are significant and the vaccine storage cold chain and trans-
portation are generally problematic and expensive in these 
countries.  
 The challenge for many developing countries remains 
how to make available to immunization services a significant 
proportion of adolescents. Delivery mechanisms need to be 
created or strengthened to reach this population, using ap-
proaches such as school-based programs, immunization 
campaigns and clinic-based programs. When targeting older 
children and adolescents with immunization, schools have 
been used extensively as a delivery venue.  
 In many settings, school-based health interventions and 
immunization delivery are widely accepted and offer the 
advantage of easy access, convenience and time efficiency 
for parents [124]. However in some countries (particularly in 
Africa), there is not always a clear correlation between age 
and academic levels in school. Thus school-based pro-
grammes have to be clear as to whether target groups are 
defined by biological age or school year. One major concern, 
not just in terms of the effectiveness of these programmes, 
but also in terms of equity, is that such a delivery strategy 
will not reach the many adolescents who do not attend 
school [125]. Achieving widespread vaccination coverage of 
adolescents in developing countries in the next 10 years will 
require a concerted global effort, given social, logistical and 
financial challenges. Reaching high coverage will require 
addressing social and cultural perceptions about vaccination, 
improving health care systems for adolescents, strengthening 
the vaccine cold chain and improving transportation. The 
challenge is compounded by the need to deliver vaccines that 
require more than one dose over an interval of months. Inno-
vative delivery strategies to reach adolescents are currently 
being investigated, building on existing immunization pro-
grams and looking for integration opportunities with other 
health priorities. 
WHAT IS THE FUTURE OF ADOLESCENT IMMUNI- 
ZATION? 
 A time when vaccines become more readily available to 
adolescents, more efforts should be made to increase cover-
age rate in this population since adolescence is the last 
opportunity for large-scale immunization programs. Identify-
ing the best strategy to ensure high vaccination rates is a 
major challenge because a lot of factors influence attitudes 
towards vaccination in teenagers. Probably a multi-level 
strategy focused on patient-oriented interventions, provider 
interventions and system interventions would be the most 
effective ones although an “individualized strategy” based 
on the social, financial and cultural resources of each country 
may also be determinant for achieving this goal. Understand-
ing the real shortcomings, needs and resources of each coun-
try regarding adolescent immunization could be of primary 
importance in order to build an effective strategy.  
 Making vaccine administration easier could also be an 
important goal for a successful adolescent immunization 
strategy. Other administration routes apart from intramuscu-
lar and deep-subcutaneous could increase vaccine acceptance 
in this age group because they are minimally invasive. New 
local administration sites offer in fact some important advan-
tages if compared with the traditional ones: reduction of ad-
verse effect rates, in particular those associated with needle 
use, a better mucosal immune response through a local IgA-
mediated stimulus, increasing patient compliance and cost 
savings. Nanotechnologies have also recently been applied to 
the manufacture of microscopic and minimally invasive de-
vices for epidermal delivery of some vaccines. Microneedle 
devices and nanopatches are being developed for effective 
and pain-free administration of vaccines across the skin bar-
rier layer [126]. Currently the role of these new technologies 
in adolescent immunization is not known but they may be 
able to positively influence attitudes toward vaccination. 
Nevertheless, patient-provider communication remains a 
vital component and the role of physicians in promoting 
health and immunization practices remains crucial. 
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